Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia.

ABSTRACT:

Background

Homozygous familial hypercholesterolaemia (HoFH) is characterized by a markedly increased risk of premature cardiovascular (CV) events and cardiac death. Lomitapide reduces low-density lipoprotein cholesterol (LDL-C) levels; however, the probable impact on LDL-C goals and CV events is unknown.

Methods

We used data collected in the first 26 weeks of the lomitapide pivotal phase 3 study (NCT00730236) to evaluate achievement of European Atherosclerosis Society (EAS) LDL-C targets. We used publicly available data reporting major adverse CV events (MACE) rates from other cohorts of HoFH patients to compare event rates for an equivalent number of patient years of exposure (98) in the lomitapide extension trial (NCT00943306).

Results

Twenty-nine patients were incl

SUBMITTER: Blom DJ 

PROVIDER: S-EPMC6011273 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature